Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297716 | 1.00 | ALDH1A1 (0.41) | ALDH1A1KDM4ECASP1MAPTMAPK1 | |
| SCHEMBL297717 | 1.00 | ALDH1A1 (0.41) | ALDH1A1KDM4ECASP1MAPTMAPK1 | |
| SCHEMBL287270 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4ECASP1MAPTMAPK1 | |
| SCHEMBL298699 | 0.73 | LMNA (0.47) | ALDH1A1KDM4ECASP1MAPTMEN1 | |
| SCHEMBL287300 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KDM4ECASP1MAPTMAPK1 | |
| SCHEMBL297907 | 0.70 | ALDH1A1 (0.45) | ALDH1A1KDM4ECASP1MAPTMAPK1 | |
| SCHEMBL298698 | 0.66 | ALDH1A1 (0.41) | ALDH1A1KDM4ECASP1MAPTMAPK1 | |
| SCHEMBL287111 | 0.62 | HTT (0.37) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL661687 | 0.60 | ERCC5 (0.43) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL7394339 | 0.60 | SLC6A1 (0.69) | ALDH1A1KDM4EMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | ALDH1A1 676/4885KDM4E 2916/4885CASP1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.